Abnormal Drug Reaction Surveillance in Patients Receiving Chemotherapy at a State-Level Cancer Institute
Not Applicable
- Conditions
- Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified siteHealth Condition 2: C00-D49- Neoplasms
- Registration Number
- CTRI/2024/03/064191
- Lead Sponsor
- ot Available
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male and female patients of all age groups receiving cancer chemotherapy and developing at least one ADR.
Patients willing to join the study after giving a written informed consent.
Exclusion Criteria
Patients receiving concurrent radiotherapy along with chemotherapy.
Patient not willing to give consent for the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To detect and assess the adverse drug reactions in patients undergoing cancer chemotherapy using WHO-UMC scale for causality.Timepoint: One time enquiry
- Secondary Outcome Measures
Name Time Method To assess the preventability of ADRs using Modified Schumock and Thornton scaleTimepoint: One time Enquiry;To assess the severity of ADRs using the Modified Hartwig and Siegel ScaleTimepoint: One time enquiry